The company
Tectonic Therapeutic, Inc.
TECX · Nasdaq
TECX stood above a rising 150-day average in 31 of the last 52 weekly readings, and has been out of that trend for the last 6 weeks. It is 30.5% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 6
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $470K
- Insider sales, 12 months
- $1.3M
- Officials’ trades on record
- 0
- Institutions holding
- 120 (+13)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 31 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Peter McNamaraChief Scientific Officer | sold | 536at $23.04 | 30 Sep 2026filed 2 Oct 2026 |
| Peter McNamaraChief Scientific Officer | sold | 43at $36.52 | 25 Aug 2026filed 26 Aug 2026 |
| Peter McNamaraChief Scientific Officer | sold | 43at $35.00 | 12 Aug 2026filed 14 Aug 2026 |
| Peter McNamaraChief Scientific Officer | sold | 172at $35.00 | 30 Jun 2026filed 1 Jul 2026 |
| Marcella K. RuddyChief Medical Officer | sold | 1,065at $30.00 | 4 May 2026filed 6 May 2026 |
| Marcella K. RuddyChief Medical Officer | sold | 1,000at $31.05 | 1 Apr 2026filed 3 Apr 2026 |
| Peter McNamaraChief Scientific Officer | sold | 6,047at $30.00 | 6 Mar 2026filed 9 Mar 2026 |
| Peter McNamaraChief Scientific Officer | sold | 215at $35.00 | 6 Mar 2026filed 9 Mar 2026 |
| Marcella K. RuddyChief Medical Officer | sold | 10,000at $30.00 | 6 Mar 2026filed 9 Mar 2026 |
| Peter McNamaraChief Scientific Officer | sold | 1,650at $25.00 | 4 Mar 2026filed 5 Mar 2026 |
| Peter McNamaraChief Scientific Officer | sold | 1,649at $22.06 | 3 Mar 2026filed 5 Mar 2026 |
| Alise ReicinChief Executive Officer | bought | 2,500at $21.10 | 11 Feb 2026filed 12 Feb 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| FMR LLCadded · filed 13 Aug 2026 | 2,830,378$97.3M | +13,884+0.5% |
| TCG Crossover Management, LLCunchanged · filed 14 Aug 2026 | 1,204,891$41.4M | 00.0% |
| Aberdeen Group plcunchanged · filed 31 Jul 2026 | 1,141,824$39.3M | 00.0% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 862,592$29.7M | +2,240+0.3% |
| First Light Asset Management, LLCadded · filed 14 Aug 2026 | 800,726$27.5M | +152,983+23.6% |
| BAKER BROS. ADVISORS LPunchanged · filed 14 Aug 2026 | 607,788$20.9M | 00.0% |
| 5AM Venture Management, LLCunchanged · filed 14 Aug 2026 | 606,660$20.9M | 00.0% |
| BRAIDWELL LPreduced · filed 14 Aug 2026 | 596,900$20.5M | -250,251−29.5% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 488,805$16.8M | +15,273+3.2% |
| Vestal Point Capital, LPadded · filed 14 Aug 2026 | 425,000$14.6M | +97,000+29.6% |
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.